Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study: A randomized, controlled trial

Annals of Internal Medicine

Volumn 131, Issue 12, 1999, Pages 935-942

  Ravn, Pernille ^a   Bidstrup, Marianne ^a   Wasnich, Richard D ^b   Davis, James W ^b   McClung, Michael R ^c   Balske, Ana ^c   Coupland, Carol ^d   Sahota, Opinder ^d   Kaur, Amarjot ^e   Daley, Marianne ^e   Cizza, Giovanni ^e  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b Hawaii Osteoporosis Center   (United States)

^c OREGON OSTEOPOROSIS CENTER   (United States)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; BLEEDING; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTALGIA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033593082     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-12-199912210-00005     Document Type: Article

References (32)

1. Osteoporosis. In Berg RL, Cassels JS, eds. The Second Fifty Years: Promoting Health and Preventing Disability. Washington, DC: National Academy Pr; 1990;76-100.
2. Cummings SR, Rubin SM, Black D. The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop. 1990;252:163-6.
3. Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor H, Black DM. The effect of alendronate on fracture-related utilization and healthcare costs: the Fracture Intervention Trial [Abstract]. J Bone Miner Res. 1998;5(Suppl):S182.
4. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736-46.
5. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100.
6. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women J Clin Endocrinol Metab. 1993;76:1399-406.
7. Liberman UA, Weiss SR, Bröil J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43.
8. Chesnut CH 3d, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144-52.
9. Devogelaer JP, Bröll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, et al. Oral alendronate induces progressive increases in bone mass of the spine, hio, and total body over 3 years in postmenopausal women with osteoporosis Bone. 1996;18:141-50.
10. Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab. 1997;82:265-74.
11. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.
12. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA. 1997;277:1159-64.
13. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al. Prevention of bone loss with alendronate in postmenopausal worren under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Eng J Med. 1998;338:485-92.
14. McClung M, Clemmesen B, Daifotis A, Gikhrist NL, Eisman J, Weinstein RS, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 1998;128:253-61.
15. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-700.
16. Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone. 1995;16:499-503.
17. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res. 1994;9:1515-23.
18. Heaney RP, Yates AJ, Santora AC 2d. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res. 1997;12:1143-51.
19. Christiansen C, Christensen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of oestroqen/gestagen replacement therapy. Lancet. 1981;1:459-61.
20. Effects of hormone therapy on bone mineral density: results from the post-menopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996;276:1389-s96.
21. Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. Br Med J (Clin Res Ed). 1988;296:1150-2.
22. Christiansen C, Riis BJ. 17-β estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab. 1990;71:836-41.
23. Abdalla HI, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol. 1985;66:789-92.
24. Stock JL, Bell NH, Chesnut CH 3d, Ensrud KE, Genant HK, Harris ST, et al. Increments n bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-7.
25. Fuleihan G el-H, Luckey M, Bauer R, Wasnick R, Krupa D, Reda C, et al. Effects of discontinuation of alendronate in early postmenopausal women [Abstract]. J Bone Miner Res. 1997;11(Suppl 1):S143.
26. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-21.
27. Wren BG, Brown L. Compliance with hormonal replacement therapy. Maturitas. 1991;13:17-21.
28. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;2:1151-4.
29. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
30. Michaëlsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ. 1998;316:1858-63.
31. Ross PD, Davis JW, Vogel JM, Wasnich RD. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int. 1990;46:149-61.
32. Melton LJ 3d, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites J Bone Miner Res. 1993;8:1227-33.